Advertisement

A cluster of disseminated small cortical lesions in MELAS: its distinctive clinical and neuroimaging features

  • Yu Hongo
  • Juntaro Kaneko
  • Hiroki Suga
  • Daisuke Ishima
  • Eiji Kitamura
  • Tsugio Akutsu
  • Yuya Onozawa
  • Naomi Kanazawa
  • Tomohide Goto
  • Kazutoshi Nishiyama
  • Takahiro IizukaEmail author
Original Communication
  • 87 Downloads

Abstract

Objectives

To investigate a diversity of stroke-like episodes (SLEs) in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and report a disseminated form of SLEs (D-SLEs) attributed to a cluster of disseminated small cortical lesions.

Methods

We retrospectively reviewed the clinical information of 27 MELAS patients seen at Kitasato University Hospital between January 1990 and April 2018. Among those, we selected 13 patients with m.3243A>G mutation [median age at onset, 35 years (11–68 years), two pediatric onset < 17 years] who had at least one SLE. SLEs were classified into classic or non-classic based on characteristic features of stroke-like lesions.

Results

44 SLEs were identified during a median observational period of 119 months (3–240 months). Among those, 29 (65.9%) were classic SLEs (C-SLEs) mainly attributed to a single continuous lobular lesion incongruent to vascular territory and occasionally accompanied by a gradual spread associated with hyperperfusion and persistent seizure activity. The remaining 15 were non-classic attributed to sparsely distributed (n = 10), disseminated (n = 4) or cerebellar lesions (n = 1). C-SLEs developed in all patients but non-classic SLEs in 5; D-SLEs developed in 4 patients accounting for 4 of 44 SLEs (9.1%). Non-classic SLEs developed more frequently in pediatric-onset than in adult-onset patients (12/15 vs. 3/29, p < 0.0001). SLEs began with acute onset of symptoms in 42 SLEs (95.5%), but D-SLEs of 2 adult-onset patients began with ill-defined subacute-onset fluctuating encephalopathy.

Conclusions

This study showed a diversity of SLEs in patients with m.3243A>G mutation. Further studies are required to elucidate the pathophysiological mechanisms of non-classic SLEs including D-SLEs.

Keywords

MELAS Stroke-like episodes Diversity Brain MRI Cerebral blood flow 

Notes

Acknowledgements

The authors thank all of the patients involved in this study and acknowledge the efforts of research staff, who worked on the clinical and neuroimaging data collection.

Author contributions

YH, NK, TI: conception of the work, data acquisition, data interpretation, drafting and revising the manuscript for intellectual content. JK, HS, DI, EK, TA, YO, TG, KN: data acquisition, data interpretation, and revising the manuscript for intellectual content.

Funding

None.

Compliance with ethical standards

Conflicts of interest

KN received grants from Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., and Eisai Co., Ltd. TI received a grant from Japan Epilepsy Research Foundation. Other authors report no disclosures.

Ethical standards

The study was approved by the Institutional Review Board of Kitasato University (B17-351).

Supplementary material

415_2019_9283_MOESM1_ESM.docx (6.4 mb)
Supplementary material 1 (DOCX 6579 KB)

References

  1. 1.
    Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP (1984) Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 16:481–488.  https://doi.org/10.1002/ana.410160409 CrossRefGoogle Scholar
  2. 2.
    Iizuka T, Sakai F (2010) Pathophysiology of stroke-like episodes in MELAS: neuron-astrocyte uncoupling in neuronal hyperexcitability. Future Neurol 5:61–83.  https://doi.org/10.2217/fnl.09.71 CrossRefGoogle Scholar
  3. 3.
    Goto Y, Nonaka I, Horai S (1990) A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348:651–653CrossRefGoogle Scholar
  4. 4.
    Kirino Y, Suzuki T (2005) Human mitochondrial diseases associated with tRNA wobble modification deficiency. RNA Biol 2:41–44CrossRefGoogle Scholar
  5. 5.
    Suzuki T, Nagao A, Suzuki T (2011) Human mitochondrial diseases caused by lack of taurine modification in mitochondrial tRNAs. Wiley Interdiscip Rev RNA 2:376–386.  https://doi.org/10.1002/wrna.65 CrossRefGoogle Scholar
  6. 6.
    Ohama E, Ohara S, Ikuta F, Tanaka K, Nishizawa M, Miyatake T (1987) Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol 74:226–233.  https://doi.org/10.1007/BF00688185 CrossRefGoogle Scholar
  7. 7.
    Sparaco M, Bonilla E, Dimauro S, Powers JM (1993) Neuropathology of mitochondrial encephalopathies due to mitochondrial DNA defects. J Neuropathol Exp Neurol 52:1–10CrossRefGoogle Scholar
  8. 8.
    Iizuka T, Sakai F, Suzuki N, Hata T, Tsukahara S, Fukuda M, Takiyama Y (2002) Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 59:816–824.  https://doi.org/10.1212/WNL.59.6.816 CrossRefGoogle Scholar
  9. 9.
    Iizuka T, Sakai F (2005) Pathogenesis of stroke-like episodes in MELAS: analysis of neurovascular cellular mechanisms. Curr Neurovasc Res 2:29–45CrossRefGoogle Scholar
  10. 10.
    Iizuka T, Sakai F, Kan S, Suzuki N (2003) Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 61:1238–1244.  https://doi.org/10.1212/01.WNL.0000091888.26232.FE CrossRefGoogle Scholar
  11. 11.
    Yoneda M, Maeda M, Kimura H, Fujii A, Katayama K, Kuriyama M (1999) Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology 53:2182–2184.  https://doi.org/10.1212/WNL.53.9.2182 CrossRefGoogle Scholar
  12. 12.
    Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T (2010) MELAS and l-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 1201:104–110.  https://doi.org/10.1111/j.1749-6632.2010.05624.x CrossRefGoogle Scholar
  13. 13.
    Davidson MM, Walker WF, Hernandez-Rosa E (2009) The m.3243A>G mtDNA mutation is pathogenic in an in vitro model of the human blood brain barrier. Mitochondrion 9:463–470.  https://doi.org/10.1016/j.mito.2009.08.006 CrossRefGoogle Scholar
  14. 14.
    Matsuzaki M, Takahashi R, Nakayama T, Shishikura K, Suzuki H, Hirayama Y, Osawa M, Oda H (2010) Disruption of endothelial tight junctions in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). Neuropediatrics 41:72–74.  https://doi.org/10.1055/s-0030-1261886 CrossRefGoogle Scholar
  15. 15.
    Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K (2018) Therapeutic regimen of l-arginine for MELAS: 9-year, prospective, multicenter, clinical research. Neurol J 265:2861–2874.  https://doi.org/10.1007/s00415-018-9057-7 CrossRefGoogle Scholar
  16. 16.
    Xie S (2014) MR OEF imaging in MELAS. Methods Enzymol 547:433–444.  https://doi.org/10.1016/B978-0-12-801415-8.00021-7 CrossRefGoogle Scholar
  17. 17.
    Iizuka T, Sakai F, Endo M, Suzuki N (2003) Response to sumatriptan in headache of MELAS syndrome. Neurology 61:577–578.  https://doi.org/10.1212/01.WNL.0000078931.87815.B3 CrossRefGoogle Scholar
  18. 18.
    Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57(Suppl 2):47–55.  https://doi.org/10.1111/head.13081 CrossRefGoogle Scholar
  19. 19.
    Iizuka T, Goto Y, Miyakawa S, Sato M, Wang Z, Suzuki K, Hamada J, Kurata A, Sakai F (2009) Progressive carotid artery stenosis with a novel tRNA phenylalanine mitochondrial DNA mutation. J Neurol Sci 278:35–40.  https://doi.org/10.1016/j.jns.2008.11.016 CrossRefGoogle Scholar
  20. 20.
    Lax NZ, Pienaar IS, Reeve AK, Hepplewhite PD, Jaros E, Taylor RW, Kalaria RN, Turnbull DM (2012) Microangiopathy in the cerebellum of patients with mitochondrial DNA disease. Brain 135:1736–1750.  https://doi.org/10.1093/brain/aws110 CrossRefGoogle Scholar
  21. 21.
    Bargalló N, Burrel M, Berenguer J, Cofan F, Buñesch L, Mercader JM (2000) Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. AJNR Am J Neuroradiol 21:479–484Google Scholar
  22. 22.
    Donaire A, Carreno M, Gómez B, Fossas P, Bargalló N, Agudo R, Falip M, Setoaín X, Boget T, Raspall T, Obach V, Rumiá J (2006) Cortical laminar necrosis related to prolonged focal status epilepticus. J Neurol Neurosurg Psychiatry 77:104–106.  https://doi.org/10.1136/jnnp.2004.058701 CrossRefGoogle Scholar
  23. 23.
    Finsterer J, Zarrouk Mahjoub S (2012) Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 8:71–79.  https://doi.org/10.1517/17425255.2012.644535 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yu Hongo
    • 1
  • Juntaro Kaneko
    • 1
  • Hiroki Suga
    • 1
  • Daisuke Ishima
    • 1
  • Eiji Kitamura
    • 1
  • Tsugio Akutsu
    • 1
  • Yuya Onozawa
    • 2
  • Naomi Kanazawa
    • 1
  • Tomohide Goto
    • 3
  • Kazutoshi Nishiyama
    • 1
  • Takahiro Iizuka
    • 1
    Email author
  1. 1.Department of NeurologyKitasato University School of MedicineSagamiharaJapan
  2. 2.Department of Clinical LaboratoryKitasato University HospitalSagamiharaJapan
  3. 3.Department of NeurologyKanagawa Children’s Medical CenterYokohamaJapan

Personalised recommendations